Quantcast
Last updated on April 18, 2014 at 10:08 EDT

Latest Nootropics Stories

2011-12-12 07:00:00

OAKLAND, Calif., Dec. 12, 2011 /PRNewswire/ -- Researchers have found little evidence of increased risk of heart attack, sudden cardiac death or stroke associated with use of medications used primarily to treat attention deficit hyperactivity disorder. Their population-based study included more than 150,000 adults aged 25-64 years who used ADHD medications. This new study, funded by the U.S. Food and Drug Administration and the Agency for Health Research Quality, is the largest --...

2011-12-01 12:00:00

PHILADELPHIA, Dec. 1, 2011 /PRNewswire/ -- Shire plc, the global specialty biopharmaceutical company, responds to questions about reports of a supply shortage of ADDERALL® (mixed salts of a single-entity amphetamine product) Tablets, CII. ADDERALL® is an immediate release formulation and is sometimes referred to as "ADDERALL IR." While Shire is aware of the reports of the supply shortage, Shire cannot provide additional information because Shire does not...

2011-11-16 08:36:00

GREENWOOD VILLAGE, Colo., Nov. 16, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has received PTO notification of the allowance of two important U.S. patents. The first patent is directed to a unique class of compounds that combine elements of diketopiperazines (same class as Ampion(TM)) and methylphenidate...

2011-11-02 14:34:00

ORLANDO, Fla., Nov. 2, 2011 /PRNewswire-USNewswire/ -- Physicians should look for signs of substance abuse in teenagers who suffer from attention deficit hyperactivity disorder (ADHD), according to Philip L. Creps, DO, who shared his concerns over the correlation between the two behavioral disorders with his fellow osteopathic physicians (DOs) during the American Osteopathic Association's (AOA) OMED 2011, the Osteopathic Medical Conference & Exposition at the Orange County Convention...

2011-10-25 09:17:00

QUEBEC CITY, Oct. 25, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that it has been issued U.S. patent No. 8,039,459 from the United States Patent & Trademark Office (USPTO) entitled "Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases." The first patent of this series in the USPTO comprises...

2011-10-24 17:51:00

ROCKVILLE, Md., Oct. 24, 2011 /PRNewswire-USNewswire/ -- Formal training in parenting strategies is a low-risk, effective method for improving behavior in preschool-age children at risk for developing attention deficit hyperactivity disorder (ADHD), while there is less evidence supporting the use of medications for children younger than 6 years old, according to a new report from the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ). The...

2011-09-21 13:05:22

MGH study demonstrates what may be first feasible method to induce arousal from anesthesia Administration of the commonly used stimulant drug methylphenidate (Ritalin) was able to speed recovery from general anesthesia in an animal study conducted at Massachusetts General Hospital (MGH). The report, appearing in the October issue of Anesthesiology, is the first demonstration in mammals of what could be a safe and effective way to induce arousal from general anesthesia. While there are...

2011-09-13 18:30:00

PRINCETON, N.J., Sept. 13, 2011 /PRNewswire/ -- Kremers Urban Pharmaceuticals Inc. is pleased to announce that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application (ANDA) to market an extended release methylphenidate hydrochloride product, for which Concerta® is the reference listed drug product. The ANDA is currently under review with FDA. The settlement includes a patent license and covenant, under existing...

2011-09-13 07:00:00

MORRISTOWN, N.J., Sept. 13, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. has launched Levetiracetam Extended-Release 500 mg and 750 mg tablets, the generic version of UCB, Inc.'s Keppra XR(®) following approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). Watson has begun shipping the product today. Keppra XR(®) is indicated...

2011-09-06 22:07:02

Universities and colleges need to do more to protect young adults from the dangers of illicit stimulant use and to educate them about harms, argue the authors of an editorial in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj111149.pdf. Students use stimulants to keep them alert to enhance their academic performance, although the perceived benefits are questionable. "The vast majority of the evidence shows no cognitive...